About Domina Therapeutics
Domina Therapeutics is a neuroscience drug discovery company on a mission to reverse cognitive decline. We are developing novel therapeutics for some of the most devastating and costly disorders of our time, such as Alzheimer’s disease, bipolar disorder, and schizophrenia. These conditions collectively cost the United States over a trillion dollars annually and affect tens of millions of people.
Our focus is long‑term value creation in the pipeline: reducing uncertainty while strengthening the scientific and clinical case for each program.
An aging global population faces an accelerating wave of cognitive decline. Standardized brain neural network models and advances in AI/ML now make deeper neural mapping possible in ways that weren’t feasible even five years ago. Recent scientific validation of neural network dysregulation well ahead of symptom onset has given us a foundation to build on. The window to get ahead of this crisis is open — and Domina is built to move through it.
Science
A New Approach to an Old Problem
For decades, neurological drug discovery has been built on flawed assumptions. The amyloid-beta hypothesis led to over 500 failed clinical trials and billions in wasted research funding. Neurotransmitter modulation approaches treat symptoms without addressing root causes, leaving patients managed rather than treated. We believe the field needs new targets — and a fundamentally better way to find them.
Domina was founded on a key scientific insight: cognitive disorders share a common underlying mechanism. Healthy cognition depends on properly formed and functioning neural network. Dendritic spines are essential to a properly functioning neural network, which is disrupted across Alzheimer’s, bipolar disorder, schizophrenia, and other neurological conditions. By targeting this early, functional read-out, we can restore healthy neural function rather than simply masking its absence.
Our Platform
At the heart of Domina is a patentable, AI-assisted target discovery platform. We develop human brain neural network models derived from patient cells, use machine learning to map neural network communication signatures, and leverage that to identify novel compounds capable of restoring neural network function. This approach has already enabled us to map distinct network signatures across Alzheimer’s, bipolar disorder, and Parkinson’s disease, and has generated validated hits in both our Alzheimer’s and bipolar programs.
The result is a clear path to first-in-class intellectual property targeting mechanisms the industry has not yet explored.
Programs
Domina’s discovery platform is designed to generate multiple therapeutic programs across cognitive disorders from a single, unified biological insight: restoring neural network function reverses cognitive decline. Our pipeline spans a few disease areas at varying stages of development, anchored by our most advanced programs in Alzheimer’s disease and bipolar disorder.
Team
Domina is led by a team of seasoned biotech professionals and research scientists with deep expertise across bioinformatics, medicinal chemistry, neuroscience, and stem cell biology.
Ravi Jain, PhD
Co-founder & CEO
Warren Wade, PhD
VP of Discovery
Evan Snyder, MD PhD
Co-founder
Bill Keating
Board
Petr Sramek
Board